Diagnostics Pipeline: Savara Introduces Blood Test to Detect aPAP, a Rare Lung Disorder
Savara’s ClearPath assay needs just a few drops of blood to test for aPAP, a condition that can be difficult and invasive to diagnose
Savara’s ClearPath assay needs just a few drops of blood to test for aPAP, a condition that can be difficult and invasive to diagnose
From - Diagnostic Testing & Emerging Technologies
Dermatopathologists are increasingly using molecular testing for diagnosis of skin cancer samples. Yet, this adoption remains more concentrated in…
From - Diagnostic Testing & Emerging Technologies
The U.S. Food and Drug Administration (FDA) recently approved the first blood test to evaluate concussions in adults…
From - Diagnostic Testing & Emerging Technologies
A blood-based screening test capable of detecting multiple forms of early cancer just took one step closer to becoming a reality. A study published…
From - Diagnostic Testing & Emerging Technologies
In an era of growing concerns over antibiotic stewardship, there is renewed interest in delabeling misidentified penicillin allergies as part of quality improvement efforts…
From - Diagnostic Testing & Emerging Technologies
Early results from an ongoing "basket study" show that targeted therapies may be effective strictly based on the tumor's molecular profile, and not primary tumor type…
From - Diagnostic Testing & Emerging Technologies
Undeniably, much of the emerging test focus is on cancer and infectious diseases. DTET wants to showcase other novel tests entering the marketplace. What follows is…